As a result, MAMPs originating from the gut, such as lipopolysaccharides or microbial RNA, can enter the portal circulation and reach the liver, activating NLRP3 inflammasome and aggravating liver inflammation and fibrosis. Here, NLRP3 is linked to digestive system neoplasm.